A detailed history of Northern Trust Corp transactions in Inhibrx, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 307,541 shares of INBX stock, worth $4.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
307,541
Previous 313,889 2.02%
Holding current value
$4.36 Million
Previous $11.9 Million 9.86%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$32.76 - $39.56 $207,960 - $251,126
-6,348 Reduced 2.02%
307,541 $10.8 Million
Q4 2023

Feb 13, 2024

SELL
$14.5 - $38.0 $22,170 - $58,102
-1,529 Reduced 0.48%
313,889 $11.9 Million
Q3 2023

Nov 13, 2023

SELL
$15.75 - $26.31 $213,869 - $357,263
-13,579 Reduced 4.13%
315,418 $5.79 Million
Q2 2023

Aug 11, 2023

BUY
$16.96 - $27.82 $184,372 - $302,431
10,871 Added 3.42%
328,997 $8.54 Million
Q1 2023

May 15, 2023

BUY
$18.45 - $27.14 $113,264 - $166,612
6,139 Added 1.97%
318,126 $6 Million
Q4 2022

Feb 13, 2023

BUY
$20.18 - $33.33 $722,363 - $1.19 Million
35,796 Added 12.96%
311,987 $7.69 Million
Q3 2022

Nov 14, 2022

BUY
$11.58 - $24.73 $185,418 - $395,976
16,012 Added 6.15%
276,191 $4.96 Million
Q2 2022

Aug 12, 2022

BUY
$8.52 - $25.26 $51,128 - $151,585
6,001 Added 2.36%
260,179 $2.95 Million
Q1 2022

May 13, 2022

SELL
$19.89 - $43.18 $140,244 - $304,462
-7,051 Reduced 2.7%
254,178 $5.66 Million
Q4 2021

Feb 08, 2022

BUY
$26.75 - $46.02 $155,123 - $266,869
5,799 Added 2.27%
261,229 $11.4 Million
Q3 2021

Nov 15, 2021

BUY
$25.18 - $37.81 $241,551 - $362,711
9,593 Added 3.9%
255,430 $8.51 Million
Q2 2021

Aug 13, 2021

BUY
$14.69 - $27.52 $2.2 Million - $4.13 Million
149,977 Added 156.45%
245,837 $6.77 Million
Q1 2021

May 12, 2021

SELL
$16.27 - $41.26 $54,341 - $137,808
-3,340 Reduced 3.37%
95,860 $1.92 Million
Q4 2020

Feb 11, 2021

BUY
$15.96 - $50.0 $1.58 Million - $4.96 Million
99,200 New
99,200 $3.27 Million

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $553M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.